

Product datasheet for TL307427V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Tumor protein D52 like 3 (TPD52L3) Human shRNA Lentiviral Particle (Locus ID 89882)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Tumor protein D52 like 3 (TPD52L3) Human shRNA Lentiviral Particle (Locus ID 89882)

Locus ID: 89882

Synonyms: D55; hD55; NYDSP25; TPD55

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: TPD52L3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: BC017589, BC033792, NM 001001874, NM 001001875, NM 033516, NM 001001875.1,

NM 001001875.2, NM 001001875.3, NM 001001874.1, NM 001001874.2, NM 033516.1, NM 033516.2, NM 033516.3, NM 033516.4, NM 033516.5, BC017589.2, BC033792.1,

BC042113, NM 001001874.3

UniProt ID: Q96|77

Summary: This gene encodes a member of the tumor protein D52-like family of proteins. These proteins

are characterized by an N-terminal coiled-coil motif that is used to form homo- and

heteromeric complexes with other tumor protein D52-like proteins. The encoded protein may play a role in spermatogenesis. Alternative splicing results in multiple transcript variants.

[provided by RefSeq, Oct 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Tumor protein D52 like 3 (TPD52L3) Human shRNA Lentiviral Particle (Locus ID 89882) – TL307427V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).